H.C. Wainwright initiated coverage of Entasis Therapeutics (NASDAQ:ETTX) with a “buy” rating and $18 price target. The stock closed at $8.25 on Aug. 16. Spun out of AstraZeneca in 2015, Entasis is focused on novel...
H.C. Wainwright downgraded Trillium Therapeutics (NASDAQ:TRIL) to “neutral” from “buy” and removed its price target, saying the precipitous fall in the stock price could lead to a cash crunch. Over the last six months...
SVB Leerink initiated coverage of Myovant Sciences (NYSE:MYOV) with an “outperform” rating and $26 price target. The stock closed at $7 on Aug. 16. “Myovant’s lead product, relugolix, is poised to become the second...
Dawson James Securities initiated coverage of BeyondSpring (NASDAQ:BYSI) with a “buy” rating and price target of $39. The stock closed at $16.21 on Aug. 15. “BeyondSpring’s [flagship molecule] Plinabulin is well...
In a new report, GMP Securities analyst Justin Keywood gives high marks to Zenabis Global’s (TSX:ZENA) strategy for becoming a leading cannabis producer in Canada. “We see Zenabis as becoming a top-five Canadian...
Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...
Brookline Capital Markets launched coverage of Vaxart (NASDAQ:VXRT) with a “buy’ rating and $6 price target. The stock closed at 66 cents on Aug. 14. Vaxart is focused on oral, recombinant vaccines that are expected to...
Steve Forte Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia...
Zenabis Global (TSX:ZENA) posted second quarter gross revenue of $26.5-million, an increase of 115%, from $12.3-million in the first quarter of 2019. “We executed at or above plan in the second quarter and, in so...
Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...
CytoDyn (OTCQB:CYDY) reported interim data from its dose-escalating trial of leronlimab monotherapy for the treatment of HIV. Leronlimab is humanized monoclonal antibody that targets CCR5, a receptor by which HIV enters...
Akari Therapeutics (NASDAQ:AKTX) received FDA fast track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT-TMA...